

Kiyohashi K, Kakinuma S, Kamiya A, Sakamoto N, Nitta S, Yamanaka H, Yoshino K, Fujiki J, Murakawa M, Kusano-Kitazume A, Shimizu H, Okamoto R, Azuma S, Nakagawa M, Asahina Y, Tanimizu N, Kikuchi A,	Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells.	Hepatology	in press		2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Morikawa H, Adachi K, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K,	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ 2a in patients with chronic hepatitis C: a nationwide multi-center cooperative study.	J Gastroenterol.	Epub ahead of print		2012
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Ttoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One	7(6)	e39175	2012
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, Hiasa	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet	13	47	2012

Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Izumi N	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis CN.	J Viral Hepat	20(1)	72-76	2012
Toyoda J, Ozeki I, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, Kumada	Virologic response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.	J Viral Hepat	20(3)	167-173	2012
朝比奈靖浩、泉並木、桶谷 眞、熊田博光、小池和彦、鈴木文孝、滝川 一、田中 篤、坪内博仁、林 紀夫、平松直樹、四柳 宏 (日本肝臓学会肝炎ガイドライン作成委員会)	C型肝炎治療ガイドライン (第1版)	肝臓	53(6)	355-395	2012
Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M,	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I-interferon-dependent innate immunity.	Hepatology	57(1)	46-58	2013
Asahina Y, Hayashi N, Izumi N, Koike K, Kumada H, Oketani M, Suzuki F, Takikawa H, Tanaka A, Tsubouchi H, Yotsuyanagi H	editors of the Drafting Committee for Hepatitis Management Guidelines. Guidelines for the Management of Hepatitis C Virus Infection.	Hepatology Research	43	1-34	2013

研究成果の刊行に関する一覧表

<p><b><u>Kurosaki M,</u></b> Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsuhashi H Izumi N.</p>	<p>Age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy in chronic hepatitis C revealed by data mining analysis.</p>	<p>Antiviral Therapy</p>	<p>17(1)</p>	<p>35-43</p>	<p>2012</p>
<p><b><u>Kurosaki M,</u></b> Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, Izumi N.</p>	<p>A model incorporating the <i>ITPA</i> genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.</p>	<p>J Med Virol</p>	<p>85(3)</p>	<p>449-58 (in press)</p>	<p>2013</p>

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Oze T;Hiramatsu N;Mita E;Akuta N; <u>Sakamoto N</u> ;Itoh Y;Izumi N;Nomura H;Hayashi N;Takehara T	A multi-center survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	Hepatol Res			2013 in press
Kiyohashi K;Kakinuma S;Kamiya A; <u>Sakamoto N</u> ;Nitta S;Yamanaka H;Yoshino K;Fujiki J;Murakawa M;Kusano-Kitazume A;Shimizu H;Okamoto R;Azuma S;Nakagawa M;Asahina Y;Tanimizu N;Kikuchi A;Nakauchi H;Watanabe M	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	Hepatology			2013 in press
Huang JT;Tseng CP;Liao MH;Lu SC;Yeh WZ; <u>Sakamoto N</u> ;Chen CM;Cheng JC	Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase.	J Virol			2013 in press

Kurosaki M;Tanaka Y;Nishida N; <u>Sakamoto N</u> ;Enomoto N;Matsuura K;Asahina Y;Nakagawa M;Watanabe M;Sakamoto M;Maekawa S;Tokunaga K;Mizokami M;Izumi N	A model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	89	449-458	2013
Nitta S; <u>Sakamoto N</u> ;Nakagawa M;Kakinuma S;Mishima K;Kusano-Kitazume A;Kiyohashi K;Murakawa M;Nishimura-Sakurai Y;Azuma S;Tasaka-Fujita M;Asahina Y;Yoneyama M;Fujita T;Watanabe M	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity	Hepatology	57 (1)	46-58	2013
Kohjima M;Enjoji M;Yoshimoto T;Yada R;Fujino T;Aoyagi Y;Fukushima N;Fukuizumi K;Harada N;Yada M;Kato M;Kotoh K;Nakashima M; <u>Sakamoto N</u> ;Tanaka Y;Nakamuta M	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C	J Med Virol	85 (2)	250-60	2013

Nakagawa M; <u>Sakamoto N</u> ;Watanabe T;Nishimura-Sakurai Y;Onozuka I;Azuma S;Kakinuma S;Nitta S;Kiyohashi K;Kusano-Kitazume A;Murakawa M;Yoshino K;Itsui Y;Tanaka Y;Mizokami M;Watanabe M;Group OLCS	Association of ITPA gene variant and serum ribavirin concentration with blood cells decline in pegylated interferon-alfa plus ribavirin therapy for chronic hepatitis C.	Hepatol Int			2012 EPub ahead of print
Yamashita A;Salam KA;Furuta A;Matsuda Y;Fujita O;Tani H;Fujita Y;Fujimoto Y;Ikeda M;Kato N; <u>Sakamoto N</u> ;Maekawa S;Enomoto N;Nakakoshi M;Tsubuki M;Sekiguchi Y;Tsuneda S;Akimitsu N;Noda N;Tanaka J;Moriishi K	Inhibition of Hepatitis C Virus Replication and Viral Helicase by Ethyl Acetate Extract of the Marine Feather Star <i>Alloeocomatella</i> polycladia	Marine Drugs	10 (4)	744-761	2012
Sakurai F;Furukawa N;Higuchi M;Okamoto S;Ono K;Yoshida T;Kondoh M;Yagi K; <u>Sakamoto N</u> ;Katayama K;Mizuguchi H	Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a	Virus Research	165 (2)	214-218	2012

Saito H;Ito K;Sugiyama M;Matsui T;Aoki Y;Imamura M;Murata K;Masaki N;Nomura H;Adachi H;Hige S;Enomoto N; <u>Sakamoto N</u> ;Kurosaki M;Mizokami M;Watanabe S	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients	Hepatol Res	42 (10)	958-965	2012
Nichols DB;Fournet G;Gurukumar KR;Basu A;Lee JC; <u>Sakamoto N</u> ;Kozielski F;Musmuca I;Joseph B;Ragno R;Kaushik-Basu N	Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives	Eur J Med Chem	49	191-9	2012
Li YJ;Wu HH;Weng CH;Chen YC;Hung CC;Yang CW;Wang RY; <u>Sakamoto N</u> ;Tian YC	Cyclophilin A and Nuclear Factor of Activated T Cells Are Essential in Cyclosporine-Mediated Suppression of Polyomavirus BK Replication	Am J Transplant	12 (9)	2348-62	2012
Kusano-Kitazume A; <u>Sakamoto N</u> ;Okuno Y;Sekine-Osajima Y;Nakagawa M;Kakinuma S;Kiyohashi K;Nitta S;Murakawa M;Azuma S;Nishimura-Sakurai Y;Hagiwara M;Watanabe M	Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication	Antimicrob Agents Chemother	56 (3)	1315-23	2012
Kurosaki M;Hiramatsu N;Sakamoto M;Suzuki Y;Iwasaki M;Tamori A;Matsuura K;Kakinuma S;Sugauchi F; <u>Sakamoto N</u> ;Nakagawa M;Yatsuhashi H;Izumi N	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis	Antivir Ther	17 (1)	35-43	2012

Kurosaki M;Hiramatsu N;Sakamoto M;Suzuki Y;Iwasaki M;Tamori A;Matsuura K;Kakinuma S;Sugauchi F;Sakamoto N;Nakagawa M;Izumi N	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C	J Hepatol	56 (3)	602-8	2012
Kobayashi T;Hige S;Terashita K;Nakai M;Horimoto H;Sho T;Nakanishi M;Ogawa K;Chuma M;Sakamoto N;Asaka M	Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C	J Gastroenterol	47 (11)	1228-37	2012
Fujimoto Y;Salam KA;Furuta A;Matsuda Y;Fujita O;Tani H;Ikeda M;Kato N;Sakamoto N;Maekawa S;Enomoto N;de Voogd NJ;Nakakoshi M;Tsubuki M;Sekiguchi Y;Tsuneda S;Akimitsu N;Noda N;Yamashita A;Tanaka J;Moriishi K	Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp	PLoS One	7 (11)	e48685	2012
Cheng JC;Yeh YJ;Tseng CP;Hsu SD;Chang YL;Sakamoto N;Huang HD	Let-7b is a novel regulator of hepatitis C virus replication	Cell Mol Life Sci	69 (15)	2621-33	2012



Asahina Y;Tsuchiya K;Muraoka M;Tanaka K;Suzuki Y;Tamaki N;Hoshioka Y;Yasui Y;Kato T;Hosokawa T;Ueda K;Nakanishi H;Itakura J;Takahashi Y;Kurosaki M;Enomoto N;Nitta S; <u>Sakamoto</u> N;Izumi N	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response	Hepatology	55 (1)	20-29	2012
--	--	------------	--------	-------	------

## 研究成果の刊行に関する一覧表

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shi N, Hiraga N, <u>Imamura M</u> , Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.	Gut			2013, in press
Hiraga N, Abe H, <u>Imamura M</u> , Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K	Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	54(3)	764-71	2011
Hiraga N, <u>Imamura M</u> , Abe H, Nelson Hayes C, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.	Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo.	Hepatology	54(3)	781-88	2011
<u>Chayama K</u> , Hayes CN, Hiraga N, Abe H, Tsuge M, <u>Imamura M</u> .	Animal model for study of human hepatitis viruses.	J Gastroenterol Hepatol	26(1)	13-18	2011
Kamiya N, Iwao E, Hiraga N, Tsuge M, <u>Imamura M</u> , Takahashi S, Miyoshi S, Tateno C, Yoshizato K, <u>Chayama K</u> .	Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.	J Gen Virol	91(Pt7)	1668-77	2010

## 研究成果の刊行に関する一覧表レイアウト (参考)

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
------	---------	---------------	-------	------	-----	-----	-----

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuda H, Ito Y, Suto H, Yamakawa A, Satomi S, Ohtani M, Yamazaki Y, Kusaka Y, Shimabukuro Y, Kikuchi K, Keida Y, Azuma T, Nakamoto Y	Clinical relevance and sequence analysis of the Helicobacter pylori dupA region from two areas in Japan with different gastric cancer risks.	Immuno-Gastroenterology	1(2)	127-135	2012
Marukawa Y, Nakamoto Y, Kakinoki K, Tsuchiyama T, Iida N, Kagaya T, Sakai Y, Naito M, Mukaida N, Kaneko S	Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.	Cancer Gene Ther.	19(5)	312-319	2012
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Kondo TH, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S	Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma.	Hepatology	(in press)		2012
Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, Kakinoki K, Fujita Y, Marukawa Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S	Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.	Clin. Exp. Immunol.	163(2)	165-177	2011

Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, <u>Nakamoto Y</u> , Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.	Gastroenterolo gy	141(1)	128-140	2011
Takata Y, <u>Nakamoto Y</u> , Nakada A, Terashima T, Arihara F, Kitahara M, Kakinoki K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S	Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma.	Cancer Lett.	307(2)	165-173	2011
Mizukoshi E, <u>Nakamoto Y</u> , Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S	Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma.	Int. J. Cancer	126(9)	2164-2174	2010
Kawano M, Nishida H, <u>Nakamoto Y</u> , Tsumura H, Tsuchiya H	Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.	Clin. Orthop. Relat. Res.	468(5)	1373-1383	2010

## 研究成果の刊行に関する一覧表 (堀田 博)

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sasase N, Kim SR, Kudo M, Kim KI, Taniguchi M, Imoto S, Mita K, Hayashi Y, Shoji I, El-Shamy A, <u>Hotta H</u>	Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.	Intervirolgy	53(1)	49-54	2010
Sanjo M, Saito T, Ishii R, Nishise Y, Haga H, Okumoto K, Ito J, Watanabe H, Saito K, Togashi H, Fukuda K, Imai Y, El-Shamy A, Deng L, Shoji I, <u>Hotta H</u> , Kawata S.	Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	82(8)	1364-1370	2010
Kim SR, Imoto S, Kudo M, Nakajima T, Ando K, Mita K, Fukuda K, Hong HS, Lee YH, Nakashima K, Shoji I, Nagano-Fujii M, <u>Hotta H</u> , Hayashi Y.	Autoimmune thrombocytopenic purpura during pegylated interferon alpha treatment for chronic hepatitis C.	Intern Med	49(12)	1119-1122	2010

Kim SR, Imoto S, Kudo M, Mita K, Taniguchi M, Kim KI, Sasase N, Shoji I, Nagano-Fujii M, El-Shamy A, <u>Hotta H</u> , Nagai T, Nagata Y, Hayashi Y.	Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics.	Intervirol	53(1)	44-48	2010
Hayashida K, Shoji I, Deng L, Jiang D-P, Ide Y-H, <u>Hotta H</u> .	17 $\beta$ -Estradiol inhibits the production of infectious particles of hepatitis C virus.	Microbiol Immunol.	54(11)	684-690	2010
Nasu J, Murakami K, Miyagawa S, Yamashita R, Ichimura T, Wakita T, <u>Hotta H</u> , Miyamura T, Suzuki T, Satoh T, Shoji I.	E6AP ubiquitin ligase mediates ubiquitin-dependent degradation of peroxiredoxin 1.	J Cell Biochem	111(3)	676-685	2010
El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, <u>Hotta H</u>	Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.	Microbiol Immunol	55(6)	418-426	2011
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, <u>Hotta H</u> , Maekawa Y, Hayashi Y, Kudo M	Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.	Digestion	84 Suppl 1	5-9	2011

Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, <u>Hotta H</u> , Kudo M	Double-filtration plasmapheresis plus interferon- $\beta$ for HCV-1b patients with non-sustained virological response to previous combination therapy.	Digestion	84 Suppl 1	10-16	2011
Nakashima K, Takeuchi K, Chihara K, <u>Hotta H</u> , Sada K	Inhibition of hepatitis C virus replication through AMP-activated protein kinase-dependent and -independent pathways.	Microbiol Immunol,	55(11)	774-782	2011
Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, Ide YH, <u>Hotta H</u>	Hepatitis C virus infection promotes Hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.	J Virol	85(17)	8556-8568	2011
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	NS5A-IRRDR変異数.	医学のあゆみ	239 (12-13)	1208-1211	2011
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	C型肝炎ウイルス NS5A領域のISDR・IRRDRとインターフェロン治療効果予測.	肝胆膵	63(6)	1063-1069	2011
El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, <u>Hotta H</u>	Polymorphisms of hepatitis C virus NS5A and core proteins and clinical outcome of pegylated Interferon/Ribavirin combination therapy.	Intervirolgy	55(1)	1-11	2012

El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, <u>Hotta H.</u>	NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon/ribavirin therapy in Egyptian patients.	J Clin Microbiol	50(12)	3886-92.	2012
El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, <u>Hotta H</u>	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.	PLoS ONE	7(2)	e30513	2012
Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, <u>Hotta H,</u> Hayashi Y.	Mutations in non-structural 5A and rapid viral response to pegylated interferon- $\alpha$ -2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.	Int J Mol Med	30(5)	1048-52.	2012
Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, <u>Hotta H.</u>	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.	J Gastroenterol	47(10)	1143-51.	2012
Kamada K, Shoji I, Deng L, Aoki C, Ratnoglik SL, Wakita T, <u>Hotta H</u>	Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production.	Microbes Infect	14(1)	69-78	2012



Matsui C, Shoji I, Kaneda S, Sianipar IR, Deng L, <u>Hotta H</u>	Hepatitis C virus infection suppresses GLUT2 gene expression via down-regulation of hepatocyte nuclear factor 1 $\alpha$ .	J Virol	86(23)	12903-11.	2012
Sasayama M, Shoji I, Adianti M, Jiang D-P, Deng L, Saito T, Watanabe H, Kawata S, Aoki C, <u>Hotta H</u>	A point mutation at ASN-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis c virus markedly enhances the sensitivity to antibody neutralization.	J Med Virol	84(2)	229-234	2012
Shoji I, Deng L, <u>Hotta H</u>	Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders.	Front Microbiol	2: A278	1-5	2012
Nakashima K, Takeuchi K, Chihara K, Horiguchi T, Sun X, Deng L, Shoji I, <u>Hotta H</u> , Sada K.	HCV NS5A protein containing potential ligands for both Src homology 2 and 3 domains enhances autophosphorylation of Src family kinase Fyn in B cells.	PLoS ONE	7(10)	e46634.	2012
El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, <u>Hotta H</u> .	Polymorphisms of the core, NS3 and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.	Hepatology	In press		
Utsumi T, Yano Y, Lusida MI, Nasronudin, Amin M, Juniastuti, Soetjipto, <u>Hotta H</u> , Hayashi Y.	Detection of highly prevalent hepatitis B virus co-infection with HIV in Indonesia.	Hepatology Res	In press		
進藤 道子, El-Shamy Ahmed, 奥野 忠雄, <u>堀田博</u> .	型慢性肝炎時から肝癌発生まで経過を追えたC型肝炎ウイルスジェノタイプ1bのコア蛋白アミノ酸多様性と肝癌発生との関連性.	肝臓	53(9)	541-548.	2012

Shimizu YK, Hijikata M, Oshima M, Shimizu K, Alter HJ, Purcell RH, Yoshikura H, <u>Hotta H.</u>	Isolation of human monoclonal antibodies to the envelope E2 protein of hepatitis C virus and their characterization.	PLoS One	8(2)	e55874	2013
--	--	----------	------	--------	------

## 研究成果の刊行に関する一覧表レイアウト (参考)

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社 名	出版地	出版年	ページ
鈴木文孝	B 型肝炎の抗ウイルス療法 ①ガイドライン【4】	熊田博光	インフォームド コンセントのた めの図説シリ ーズ	医薬ジャーナル社	大阪	2012	28-31

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin	Hepatology	52	421-429	2010
Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H.	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J Clinic virol	47	76-78	2010

Arase Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Hosaka T, Kawamura Y, Yatsuji H, Hirakawa M, Ikeda K, Kobayashi M, Kumada H.	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.	J Med Virol	82	390-395	2010
Kobayashi M, <u>Suzuki F</u> , Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H.	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.	Hepatology Res	40	125-134	2010
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.	Hepatology Res	40	145-152	2010
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, <u>Suzuki F</u> , Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatology Res	40	1-7	2010
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, <u>Suzuki F</u> , Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatology Res	40	8-13	2010
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.	J Med Virol	82	575-582	2010